ANTHONY JOSEPH PIRAINO
Medical Practice in Delaware
License number
Pennsylvania MD034163E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Delaware
Media, PA 19063
Media, PA 19063
Personal information
See more information about ANTHONY JOSEPH PIRAINO at radaris.comName
Address
Phone
52 Delia Dr, Broomall, PA 19008
511 Chestnut St, Ridley Park, PA 19078
53 Lawson Ave, Claymont, DE 19703
10 Florence Ave, Collingdale, PA 19023
142 Wagner Blvd, Greenfild Twp, PA 18407
Professional information
Dr. Anthony J Piraino, Wilmington DE - MD (Doctor of Medicine)
Specialties:
Internal Medicine, Dermatology, Psychoanalysis
Address:
1800 Concord Pike, Wilmington 19897
(302) 885-8456 (Phone), (302) 885-8456 (Fax)
PIRAINO, ANTHONY J MD PHD
172 Dam View Rd, Media 19063
(610) 891-1860 (Phone)
(302) 885-8456 (Phone), (302) 885-8456 (Fax)
PIRAINO, ANTHONY J MD PHD
172 Dam View Rd, Media 19063
(610) 891-1860 (Phone)
Languages:
English
Education:
Medical School
Drexel University College of Medicine
Graduated: 1984
Washington Center / School of Medicine
Graduated: 1938
Drexel University College of Medicine
Graduated: 1984
Washington Center / School of Medicine
Graduated: 1938
Anthony Piraino, Media PA
Work:
Astrazeneca Pharmaceuticals
172 Dam View Rd, Media, PA 19063
172 Dam View Rd, Media, PA 19063
Method Of Reducing Serum Uric Acid And/Or Increasing Renal Uric Acid Clearance With Thromboxane Synthetase Inhibitor Inhibitor And/Or Thromboxane Receptor Antagonist
US Patent:
5021448, Jun 4, 1991
Filed:
Feb 22, 1990
Appl. No.:
7/483160
Inventors:
Anthony J. Piraino - Media PA
Steven D. Saris - Ardmore PA
Steven D. Saris - Ardmore PA
Assignee:
Ciba-Geigy Corporation - Ardsley NY
International Classification:
A61K 31415, A61K 3140, A61K 3134, A61K 31335, A61K 31265, A61K 3118, A61K 31135, A61K 31095, A61K 3110, A61K 31075, A61K 31045, A61K 3105, A61K 3144
US Classification:
514415
Abstract:
A method of reducing serum uric acid and/or increasing renal clearance of uric acid in a mammal in need thereof comprising administering to such mammal a uricosuric effective amount of a thromboxane synthetase inhibitor, a thromboxane receptor antagonist, or both in a combined uricosuric effective amount is disclosed. Compositions having one or more of the foregoing in combination with one or more known uricosurics are also set forth.